PT  - JOURNAL ARTICLE
AU  - Teja Muralidhar Kalidindi
AU  - Sang-Gyu Lee
AU  - Katerina Jou
AU  - Goutam Chakraborty
AU  - Myrto Skafida
AU  - Scott T. Tagawa
AU  - Neil H. Bander
AU  - Heiko Schoder
AU  - Lisa Bodei
AU  - Neeta Pandit-Taskar
AU  - Jason S. Lewis
AU  - Steven M. Larson
AU  - Joseph R. Osborne
AU  - Naga Vara Kishore Pillarsetty
TI  - A simple strategy to reduce the salivary gland and kidney uptake of PSMA targeting small molecule radiopharmaceuticals
AID  - 10.1101/2020.07.24.220277
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.07.24.220277
4099  - http://biorxiv.org/content/early/2020/07/26/2020.07.24.220277.1.short
4100  - http://biorxiv.org/content/early/2020/07/26/2020.07.24.220277.1.full
AB  - The past five years have seen an increasing acceptance of peptide-based prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) agents for treatment of metastatic castration-resistant prostate cancer (mCRPC), with [177Lu]-DKFZ-PSMA-617 ([177Lu]-PSMA-617) emerging as the leading candidate. [177Lu]-PSMA-617 and other PSMA ligands have shown efficacy in reducing the tumor burden in mCRPC patients but irradiation to salivary gland and kidneys is a concern and dose limiting factor. Therefore, methods to reduce non-target organ toxicity are needed to safely treat patients and preserve their quality of life. Here, we report the effects of the addition of the cold PSMA ligand DKFZ-PSMA-11 (PSMA-11) on the uptake of [177Lu]-PSMA-617 in tumor, salivary glands and kidneys. Groups of athymic nude mice (n = 4) bearing PC3-PIP (PSMA+) tumor xenografts were administered with [177Lu]-PSMA-617 along with 0, 5, 100, 500, 1000 and 2000 pmoles of PSMA-11. Biodistribution studies 1 h post-administration revealed that [177Lu]-PSMA-617 uptake in PSMA-expressing PC3-PIP tumors was 21.71±6.13, 18.7±2.03, 26.44±2.94, 16.21±3.5, 13.52±3.68, and 12.03±1.96 %ID/g when 0, 5, 100, 500, 1000 and 2000 pmoles of PSMA-11 were added, respectively. Corresponding kidney uptake values were 123.14±52.52, 132.31±47.4, 84.29±78.25, 2.12±1.88, 1.16±0.36, 0.64±0.23 %ID/g, respectively. Corresponding salivary gland uptake values were 0.48±0.11, 0.45±0.15, 0.38±0.3, 0.08±0.03, 0.09±0.07, 0.05±0.02 % ID/g, respectively. Thus, uptake of PSMA TRT agents in salivary gland and kidney can be substantially reduced without impact on tumor uptake by adding cold PSMA-11. Our data provides proof-of-concept and we propose that similar strategy be pursued in future clinical trials to prevent xerostomia and renal toxicity arising from [177Lu]-PSMA-617.Competing Interest StatementThe authors have declared no competing interest.